To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma



Eligible Ages
Over 18 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • HLA-A*02:01-positive. - unresectable Stage III or Stage IV non-ocular melanoma - archival tumor tissue sample or a newly obtained biopsy of a tumor lesion not previously irradiated has been provided. - measurable or non-measurable disease per RECIST 1.1 - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - If applicable, must agree to use highly effective contraception - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol

Exclusion Criteria

  • Pregnant or lactating women - diagnosis of ocular or metastatic uveal melanoma - history of a malignant disease other than those being treated in this study - ineligible to be retreated with pembrolizumab due to a treatment-related AE - known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis - previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) - active autoimmune disease requiring immunosuppressive treatment - clinically significant medical condition - known psychiatric or substance abuse disorders - received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication - received chemotherapy or biological cancer therapy (excluding anti-PD(L)1 mAb, ipilimumab, and BRAF TKI regimen) within 14 days of first dose - received cellular therapies within 90 days of first dose - received systemic treatment with steroids or any other immunosuppressive drug within 2 weeks of first dose - have not progressed on treatment with an anti-PD(L)1 mAb - have not received prior ipilimumab - a BRAF V600 mutation, who have not received a prior BRAF/MEK TKI regimen - currently participating or have participated in a study of an investigational agent or using an investigational device within 30 days of the first dose - known history of chronic viral infections - Out of range Laboratory values - history of allogenic tissue/solid organ transplant

Study Design

Phase 2/Phase 3
Study Type
Intervention Model
Parallel Assignment
Primary Purpose
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Arm A
Tebentafusp as single agent
  • Drug: Tebentafusp
    soluble gp100-specific T cell receptor with anti-CD3 scFV
Arm B
Tebentafusp in combination with Pembrolizumab
  • Drug: Tebentafusp with Pembrolizumab
    soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with Pembrolizumab
Arm C
Straight to on protocol survival follow up including investigators choice of therapy
  • Drug: Investigators Choice
    Investigators choice of therapy

Recruiting Locations

Massachusetts General Hospital
Boston, Massachusetts 02114

More Details

Immunocore Ltd

Study Contact

Howard Goodall
+00 800-74451111

Detailed Description

This is a Phase 2/3, multicenter, open-label study to evaluate the efficacy and safety of tebentafusp as monotherapy (Arm A) and in combination with pembrolizumab (Arm B) compared with standard of care or best supportive care (Arm C) in participants with non-ocular advanced melanoma who have progressed on a prior anti-PD(L)1 regimen, received prior ipilimumab and, if the participant has a BRAF mutation, a prior BRAF tyrosine kinase inhibitor (TKI) regimen.


Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.